Drugs.com - Clinical Trials

Eneboparatide Met Primary Endpoint of Normalising Serum Calcium in Adults with Hypoparathyroidism at 24 weeks in CALYPSO Phase III Trial

March 17, 2025 -- High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical significance in adults with...

Mar 17, 2025 - 23:19
 0
Eneboparatide Met Primary Endpoint of Normalising Serum Calcium in Adults with Hypoparathyroidism at 24 weeks in CALYPSO Phase III Trial
March 17, 2025 -- High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical significance in adults with...
Read More

Tags:

Previous Article

DOGE order leads to journal cancellations by U.S. agricultural library

Next Article

Taking a look at tariffs with S&P Global Market Intelligence Economist Paul Bingham

Related Posts

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune HPV in HPV16-Positive Head and Neck Cancer

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Tr...

Mar 9, 2025  0

Depemokimab Delivers Clinically Meaningful and Statistically Significant Improvements for Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Depemokimab Delivers Clinically Meaningful and Statisti...

Mar 3, 2025  0

BioArctic Receives Orphan Drug Designation for Exidavnemab the US

BioArctic Receives Orphan Drug Designation for Exidavne...

Mar 18, 2025  0